In 2021, IGI’s Public Impact Team launched a year-long Affordability Task Force (ATF) project aimed at solving one of the trickiest challenges for genomic medicines. The report was released in July 2023 and "is the conclusion of a yearlong deliberation by 30 individuals with expertise...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting details: Tuesday,...